2026-01-24 - Analysis Report
**Company Overview:**
Johnson & Johnson is a multinational healthcare company involved in the development and sale of pharmaceuticals, medical devices, and consumer packaged goods.

**Return Rate Comparison:**
- Cumulative return of review stock (JNJ): 77.70%
- Cumulative return of comparison stock (S&P 500, VOO): 126.41%
- Divergence: -48.70 (max: 14.20, min: -91.70, current: -48.70, relative divergence: 40.60%)
- JNJ's return rate is lower than the S&P 500, indicating a divergence of 48.70%.

**Alpha, Beta Analysis:**
| **Year** | **CAGR** | **MDD** | **Alpha** | **Beta** | **Cap(B)** |
|---------|--------|---------|----------|---------|-----------|
| 2016-2018 | 6.0%   | 16.9%   | -6.0%     | 0.7     | 310.9B    |
| 2017-2019 | 21.0%  | 16.9%   | -5.0%     | 0.7     | 351.4B    |
| 2018-2020 | 13.0%  | 26.1%   | -12.0%    | 0.7     | 379.2B    |
| 2019-2021 | 27.0%  | 26.1%   | -38.0%    | 0.6     | 412.2B    |
| 2020-2022 | 17.0%  | 26.1%   | 10.0%     | 0.5     | 425.6B    |
| 2021-2023 | -10.0% | 14.3%   | -30.0%    | 0.3     | 377.6B    |
| 2022-2024 | -23.0% | 14.3%   | -53.0%    | 0.2     | 348.4B    |
| 2023-2025 | 37.0%  | 14.3%   | -38.0%    | 0.1     | 498.6B    |

**Recent Stock Price Fluctuations:**
- Close: $220.14
- Last-market: {'price': 220.14, 'previousClose': 218.49, 'change': 0.76}
- 5-day SMA: $218.70
- 20-day SMA: $211.30
- 60-day SMA: $203.76
- Recent price fluctuation is a sharp rebound.

**RSI, PPO Index Indicators and Others:**
- Market Risk Indicator (MRI): 0.70 (High Investment Recommended: 0.9~1.0, Medium Investment: 0.7~0.9)
- RSI: 72.69
- PPO: 0.38
- Hybrid Signal: Buy (Cash 0%)
- Risk Level: Medium
- Recent (20 days) relative divergence change: 1.40 (+): improving
- 7-day Rank change: 86 (+): rank up
- 7-day Dynamic Expected Return change: -25.70 (-): worsening
- Expected Return (%): -64.10%, Expected excess return compared to S&P 500 if invested long-term (more than 2 years) from this point.

**Recent News & Significant Events:**
- [2026-01-22] How Two Rivals Undercut J&J's Beat And Big Guidance - Investor's Business Daily
- [2026-01-21] Netflix, Kraft Heinz and Johnson & Johnson fall premarket; United Airlines rises - Investing.com
- [2026-01-21] Johnson & Johnson forecasts 2026 profit above Wall Street estimates - CNBC
- [2026-01-23] Johnson & Johnson Quietly Triggers a Trend Following Buy Signal - MarketBeat
- [2026-01-23] How Johnson & Johnson’s 2025 Beat and 2026 Sales Guidance Could Shape JNJ Investors’ Outlook - Yahoo Finance New Zealand
- [2026-01-21] Johnson & Johnson (NYSE:JNJ) Beats Q4 Estimates but Stock Dips on 2026 Guidance - Chartmill

**Analyst Opinions:**
- Analyst Consensus:
  * Key: Buy
  * Mean (1=StrongBuy~5=Sell): 2.21 (~Buy)
  * Opinions: 24
  * Target Price (avg/high/low): 224.09 / 265.00 / 155.00

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
|------|-----|---------|
| 2025-10-22 | 2.14 | 23.99 B$ |
| 2025-07-24 | 2.3  | 23.74 B$ |
| 2025-04-23 | 4.57 | 21.89 B$ |
| 2024-10-23 | 1.12 | 22.47 B$ |
| 2025-01-22 | 1.12 | 22.47 B$ |

**Revenue and Profitability:**
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B  | 69.56%        |
| 2025-06-30 | $23.74B  | 67.87%        |
| 2025-03-31 | $21.89B  | 66.40%        |
| 2024-12-31 | $22.52B  | 68.35%        |

**Capital and Profitability:**
| Quarter | Equity | ROE       |
|---------|---------|-----------|
| 2025-09-30 | $79.28B | 6.50%     |
| 2025-06-30 | $78.47B | 7.06%     |
| 2025-03-31 | $78.11B | 14.08%    |
| 2024-12-31 | $71.49B | 4.80%     |

**Comprehensive Analysis:**
JNJ has a lower return rate compared to the S&P 500. Recent stock price fluctuation is a sharp rebound. The MRI is at a medium-low risk level. Analyst consensus is buy with a target price of 224.09. Recent earnings have shown a decline in revenue and a decrease in profit margin. Equity has increased, but ROE has decreased. Overall, this indicates a mixed performance for JNJ.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.